纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

x 关闭永久关闭

《药学实践与服务》杂志目前不收取审稿费、版面费、加急费等费用，如收到邮件声称是编辑部X编辑，要求加作者微信的，请谨防财产损失！编辑部用于作者校对时绑定微信的邮件通过yxsjzzs@163.com发送，标题是《药学实践与服务》XML数字出版服务微信绑定，请区分开。

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

陈自强, 张玮, 李玉平, 王晓宇

文章导航 > 药学实践与服务 > 2016 > 34(2): 103-105

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

引用本文:

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

Citation:

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

doi: 10.3969/j.issn.1006-0111.2016.02.002

1.
第二军医大学附属长海医院骨科, 上海 200433
2.
同济大学附属上海市肺科医院药剂科, 上海 200433
3.
第二军医大学附属长海医院药学部, 上海 200433

Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma

1.
Department of Orthopaedics, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China
2.
Department of Pharmacy, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, China
3.
Department of Pharmacy, Changhai Hospital Affiliated to Second Military Medical University, Shanghai 200433, China

摘要: 多药耐药是肿瘤化疗中的重要难题,多药耐药的机制复杂,目前尚无有效的治疗策略。纳米载药系统具有靶向性、载药种类多样等优点,近年来成为对抗肿瘤多药耐药的递药载体的重要研究方向。对肿瘤抑制的不同机制进行讨论,并对纳米载药系统逆转骨肉瘤多药耐药的研究进展进行综述。
- 肿瘤 /
- 骨肉瘤 /
- 多药耐药 /
- 纳米载药系统
Abstract: Multidrug resistance(MDR) of tumor cell is the major problem for chemotherapy. However, there is no effective strategy to overcome MDR due to the complicated mechanism. The nano-sized drug delivery system could target to the tumor cell. Moreover, it could delivery different kinds of drugs. Therefore, the nano-sized drug delivery system has become a promising approach to reverse MDR. The nano-sized drug delivery system which is applied to treat the MDR of tumor(osteosarcoma) was summarized and the reverse mechanism was discussed.
- tumor /
- osteosarcoma /
- MDR /
- nano-sized drug delivery system

[1]	Palakurthi S, Yellepeddi VK, Vangara KK. Recent trends in cancer drug resistance reversal strategies using nanoparticles[J]. Expert Opin Drug Deliv, 2012, 9(3):287-301.
[2]	Shapira A, LivneyY D, Broxterman H J, et al. Nanomedicine for targeted cancer therapy:towards the overcoming of drug resistance[J]. Drug Resist Updat, 2011, 14(3):150-163.
[3]	Patil YB, Swaminathan SK, Sadhukha T, et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance[J]. Biomaterials, 2010, 31(2):358-365.
[4]	Song XR, Cai Z, Zheng Y, et al. Reversion of multidrug resistance by coencapsulation of vincristine and verapamil in PLGA nanoparticles[J]. Eur J Pharm Sci, 2009, 37(3-4):300-305.
[5]	Khdair A, Handa H, Mao GZ, et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro[J]. Eur J Pharm Biopharm, 2009, 71(2):214-222.
[6]	Lee ES, Gao ZG, Kim D, et a1. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e)specific TAT exposure and multidrug resistance[J]. J Control Rel, 2008, 129(3):228.
[7]	Chen B, Sun Q, Wang X, et al. Reversal in multidrug resistance by magnetic nanoparticle of Fe₃O₄ loaded with adriamycin and tetrandrine in K562/A02 leukemic cells[J]. Int J Nanomedicine, 2008, 3(2):277-286.
[8]	Chen BA, Cheng J, Shen MF, et al. Magnetic nanoparticle of Fe₃O₄ and 5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin in leukemia cells[J]. Int J Nanomedicine, 2009, 4:65-71.
[9]	Chen BA, Lai BB, Cheng J, et al. Daunorubicin-loaded magnetic nanoparticles of Fe₃O₄ overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo[J]. Int J Nanomed, 2009, 4:201-208.
[10]	Chen AM, Zhang M, Wei DG, et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells[J]. Small, 2009, 5(23):2673-2677.
[11]	WangY, Saad M, Pakunlu RI, et al. Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor[J]. Clin Cancer Res, 2008, 14(11):3607-3616.
[12]	Devalapally H, Duan ZF, Seiden MV, et al. Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles[J]. Clin Cancer Res, 2008,14(10):3193-3203.
[13]	Fan L, Li F, Zhang HT, et al. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance[J]. Biomaterials, 2010, 31(21):5634-5642.
[14]	Susa M, Iyer AK, Ryu K, et al. Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma[J]. BMC Cancer,2009, 9:399.
[15]	Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1(MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma[J]. PLoS One, 2010, 5(5):e10764.

[1]	郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛. 醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2025, 43(3): 136-142, 150. doi: 10.12206/j.issn.2097-2024.202310043
[2]	葛鹏程, 苏日古嘎, 任天舒, 党大胜. 硫酸黏菌素联合头孢哌酮舒巴坦治疗泛耐药鲍曼不动杆菌肺内感染的疗效分析 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202404093
[3]	曹奇, 张嘉宝, 王培. 基于无监督自动降维分析与手动圈门联用的骨骼肌髓系细胞多色流式分析方法 . 药学实践与服务, 2025, 43(3): 118-122. doi: 10.12206/j.issn.2097-2024.202404077
[4]	姚小静, 计佩影, 陆峰, 施国荣, 傅翔. 表面增强拉曼光谱法快速测定尿液中曲马多的研究 . 药学实践与服务, 2025, 43(4): 185-189. doi: 10.12206/j.issn.2097-2024.202401072
[5]	晁亮, 王辉, 沈淑琦, 游飘雪, 冀凯宏, 洪战英. 基于UHPLC-Q/TOF-MS代谢组学策略的葛根-知母药对防治阿尔茨海默病的药效与作用机制研究 . 药学实践与服务, 2025, 43(1): 30-40. doi: 10.12206/j.issn.2097-2024.202409035
[6]	冯一帆, 严啸东, 张文彬, 李炳锋, 郭美丽. 菸花苷长期给药对脑缺血再灌注损伤大鼠神经功能的影响 . 药学实践与服务, 2025, 43(): 1-7. doi: 10.12206/j.issn.2097-2024.202407038
[7]	崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华. 肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2025, 43(1): 6-9, 21. doi: 10.12206/j.issn.2097-2024.202404006
[8]	施乔, 韩贵焱, 张俊腾, 刘娜. 新型Hsp90抑制剂的设计合成及其抗真菌和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(3): 124-135. doi: 10.12206/j.issn.2097-2024.202501019
[9]	魏雨辰, 田家盛, 王道鑫, 凌期盛, 王治, 缪朝玉. 烟酰胺单核苷酸口服给药对高血压大鼠的影响 . 药学实践与服务, 2025, 43(5): 1-9. doi: 10.12206/j.issn.2097-2024.202412006
[10]	吴若南, 汤文敏, 高林, 吴岳林, 罗川, 缪震元. RRx-001衍生物的合成和抗肿瘤活性研究 . 药学实践与服务, 2025, 43(): 1-5. doi: 10.12206/j.issn.2097-2024.202408053
[11]	周娇, 郑建雨, 王思真, 杨峰. mRNA肿瘤疫苗非病毒递送系统研究进展 . 药学实践与服务, 2025, 43(3): 109-116. doi: 10.12206/j.issn.2097-2024.202410034
[12]	史生辉, 石飞, 雷琼, 王亚峰, 吴雪花. 青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
[13]	邹思, 吴岩斌, 吴锦忠, 吴建国, 黄家兴. 虎奶菇菌核多糖功能化纳米硒抗疲劳功效研究 . 药学实践与服务, 2024, 42(10): 426-432. doi: 10.12206/j.issn.2097-2024.202206072
[14]	陈怡君, 王卓, 何苗, 张宇, 田泾. 泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
[15]	钱淑雨, 李铁军. 耐碳青霉烯类肠杆菌耐药机制的研究进展 . 药学实践与服务, 2024, 42(10): 419-425. doi: 10.12206/j.issn.2097-2024.202405005
[16]	黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉. 耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
[17]	瞿文君, 白若楠, 崔力, 周琰. 基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
[18]	张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英. 二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
[19]	陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠. UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082

WeChat

点击查看大图

计量

文章访问数: 3418
HTML全文浏览量: 352
PDF下载量: 14
被引次数: 0

纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展

doi: 10.3969/j.issn.1006-0111.2016.02.002

1. 第二军医大学附属长海医院骨科, 上海 200433

2. 同济大学附属上海市肺科医院药剂科, 上海 200433

3. 第二军医大学附属长海医院药学部, 上海 200433

收稿日期: 2014-12-21
修回日期: 2015-05-06

关键词:

纳米载药系统

摘要: 多药耐药是肿瘤化疗中的重要难题,多药耐药的机制复杂,目前尚无有效的治疗策略。纳米载药系统具有靶向性、载药种类多样等优点,近年来成为对抗肿瘤多药耐药的递药载体的重要研究方向。对肿瘤抑制的不同机制进行讨论,并对纳米载药系统逆转骨肉瘤多药耐药的研究进展进行综述。

English Abstract

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

引用本文:

陈自强, 张玮, 李玉平, 王晓宇. 纳米载药系统逆转肿瘤及骨肉瘤多药耐药的研究进展[J]. 药学实践与服务, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

Citation:

CHEN Ziqiang, ZHANG Wei, LI Yuping, WANG Xiaoyu. Progress on nano-sized drug delivery system reversing tumor and multidrug resistance of osteosarcoma[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(2): 103-105. doi: 10.3969/j.issn.1006-0111.2016.02.002

全文HTML

参考文献 (15)

/

下载: 全尺寸图片幻灯片

分享

用微信扫码二维码

分享至好友和朋友圈

返回

版权所有：《药学实践与服务》编辑委员会

主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号沪ICP备05003363号-1

本系统由北京仁和汇智信息技术有限公司开发